Paul Terasaki

Source: Wikipedia, the free encyclopedia.
Paul I. Terasaki
UCLA
Known fororgan transplant medicine; tissue typing
AwardsUCLA Terasaki Life Sciences Building

Paul Ichiro Terasaki (

UCLA School of Medicine
.

He spent three high school years during World War II

UCLA and was appointed to the medical school faculty.[1]

In 1964, Terasaki developed the microcytotoxicity test, a tissue-typing test for organ transplant donors and recipients that required only 1 microliter each of antisera used to identify

humoral theory of transplant rejection, which states that antibodies cause allograft rejection.[3] He and his corporation, One Lambda
, have played a central role in the development of tissue typing and transplantation surgery.

Terasaki established UCLA's HLA laboratory,

retired
from UCLA, but within a year resumed his academic pursuits with the creation of the Terasaki Foundation, a research center dedicated to cancer immunotherapy and the study of humoral immunity and transplantation.

On May 13, 2010, UCLA announced the naming of the new life science building for Terasaki, who has given $50 million to the Division of Life Sciences in the UCLA College of Letters and Science, which is the largest ever given to the UCLA College. The structure is known as the Terasaki Life Sciences Building.[5] He was awarded the 2011 UCLA Edward A. Dickson Alumnus of the Year award on April 13, 2012, and the UCLA medal on June 15, 2012.

Paul Terasaki was married to artist Hisako Terasaki; they had four children.

He died on January 25, 2016, after a long illness.[6]

Publications

  • Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998–1000.
  • Terasaki PI. Resolution by HLA testing of 1000 paternity cases not excluded by ABO testing. J Family Law 1977; 16: 543–557.
  • Scholsstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HLA antigen, w27, with ankylosing spondylitis. N Engl J Med 1973; 228: 704–706.
  • Collins GM, Bravo-Shugarman M, Terasaki PI. Kidney preservation for transportation. Initial perfusion and 30 hour ice storage. Lancet 1969; ii: 1219.
  • Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years’ experience with national sharing of HLA matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343: 1078–1084.
  • Terasaki PI, Marchioro TL, Starzl TE. Serotyping of human lymphocyte antigens. Preliminary trials on long-term kidney homograft survivors. Nat Acad Sci Monograph 1965; 83–96.
  • Terasaki PI, ed. History of HLA. Ten Recollections. Los Angeles: UCLA Tissue Typing Laboratory; 1990.
  • Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735–739.
  • Nishikawa K, Terasaki PI. Annual trends and triple therapy – 1991–2000. In: Cecka, JM, Terasaki, PI, eds. Clinical Transplants 2001. Los Angeles: UCLA Immunogenetics Center; 2002, pp. 247–270.
  • Terasaki PI. Red cell crossmatching for heart transplants (letter). N Engl J Med 1991; 325: 1748.
  • Mickey MR, Kreisler M, Albert ED, Tanaka N, Terasaki PI. Analysis of HLA incompatibility in human renal transplants. Tissue Antigens 1971; 2: 57–67.
  • Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333–336.
  • Terasaki PI, Mickey MR, Kreisler M. Presensitization and kidney transplant failures. Postgrad Med 1970; 47: 89–100.
  • Opelz G, Sengar DPS, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973; 4: 253–259.
  • Terasaki PI, Cho YW, Cecka JM. Editorial: Strategy for eliminating the kidney shortage. In: Cecka, M, Terasaki, PI, eds. Clinical Transplants 1997. Los Angeles: UCLA Tissue Typing Laboratory; 1998, pp. 265–267.
  • Mckenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69:319–326.
  • Lee PC, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192–1194.
  • Terasaki PI. Antibody response to homografts. I. Preliminary studies of the time of appearance of lymphoagglutinins upon homografting. Am Surg 1959; 11: 896–899.
  • Terasaki PI. The humoral theory of transplantation. Am J Transpl 2003; 3: 665–673.
  • Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol. 2005；17(5):541-5.
  • Cai J, Terasaki PI. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol. 2005；66(4):334-42.
  • Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation. 2008;86(3):377-83
  • Cho YW, Terasaki PI, Cecka JM, Gjertson DW. Transplantation of kidneys from donors whose heart has stopped beating. N Engl J Med 1998; 338: 221–225.
  • LCCN 97090921
    .
  • LCCN 77155060
    .
  • Paul I. Terasaki, ed. (1980). Histocompatibility testing, 1980 : report of the eighth International Histocompatibility Workshop held in Los Angeles, California, USA, 4–10 February 1980. Los Angeles, Calif.: UCLA Tissue Typing Laboratory.
    LCCN 80036737
    .
  • Paul I. Terasaki, ed. (1970). Histocompatibility testing 1970; report of an international workshop held at UCLA and Palm Springs, California, U.S.A. 20-26, January 1970 and the Fourth International Histocompatibility Conference at Los Angeles, California, U.S.A. 27-29, January 1970.
    LCCN 73026161
    .
  • Jawahar L. Tiwari; Paul I. Terasaki (1985). HLA and disease associations. New York:
    LCCN 84020294
    .
  • Paul I. Terasaki, ed. (1982). Blood transfusion and transplantation. New York: Grune & Stratton.
    LCCN 82082458
    .

References

  1. ^ Stuart Wolpert (2010-05-13). "Paul Terasaki donates $50 million to UCLA's Life Sciences | UCLA". Newsroom.ucla.edu. Retrieved 2016-01-30.
  2. ^ J. Michael Cecka (14 Aug 2003). "Interview with Dr. Paul I. Terasaki" (PDF). American Journal of Transplantation. 3 (9).
    PMID 12919082. Retrieved 2008-12-13.[dead link
    ]
  3. ^ Am J Transplant. 2003 Jun;3(6):665-73
  4. ^ "UCLA Department of Pathology & Laboratory Medicine". David Geffen School of Medicine at UCLA. Archived from the original on 2010-07-06. Retrieved 2008-12-13. Training is also available in cellular immunology through the UCLA immunogenetics laboratory. This world-renowned HLA laboratory was founded by Dr. Paul I. Terasaki, and is now an integrated component of the Division of Laboratory Medicine.
  5. ^ Larry Gordon, Retired UCLA professor pledges $50 million to Westwood campus, Los Angeles Times, May 13, 2010
  6. ^ Renaud, Jean-Paul; Wolpert, Stuart. "Paul Terasaki, 86, transplant medicine pioneer, philanthropist, UCLA faculty member and alumnus". newsroom.ucla.edu. UCLA. Retrieved 2016-01-28.

External links

  • "Paul I. Terasaki - Real People". Discover Nikkei. International Nikkei Research Project. Retrieved 2008-12-13. See also its links to oral history video clips.
  • Starzl TE. The Puzzle People – Memoirs of a Transplant Surgeon. Pittsburgh, PA: University of Pittsburgh Press; 1992.
  • Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333–1338.
  • El-Awar N, Terasaki P, Lazda V, Nikaein A, Manning C, Arnold AN. Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies. Transplant Proc 2002; 34:2531–2532.
  • Halloran PF. Call for revolution: a new approach to describing allograft deterioration. Am J Transpl 2002; 2: 195–200.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Paul_Terasaki&oldid=1188221202"